Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Total article views   HTML views PDF downloads Totals
15,295 Dovepress* 13,940+ 1,795 15,735
PubMed Central* 1,355 477 1,832
Totals 15,295 2,272 17,567
*Since 6 June 2019

View citations on PubMed Central and Google Scholar